Category:Statins

**statin**
	class of drugs used to lower cholesterol levels
	Upload media
	Wikipedia
Instance of	drug class; group or class of chemical entities;
Subclass of	medication; anticholesteremic agents; enzyme inhibitor; oxidoreductase inhibitor;
Part of	response to statin (reactant);
Authority file
	Q954845; Library of Congress authority ID: sh00001691; NL CR AUT ID: ph602573; BabelNet ID: 00051454n; J9U ID: 987007285397905171
	Reasonator; Scholia; Wikidocumentaries; PetScan; statistics; WikiMap; Locator tool; KML file; Search depicted;

Subcategories

This category has only the following subcategory.

H

HMG-CoA reductase inhibitors (9 C, 24 F)

Media in category "Statins"

The following 42 files are in this category, out of 42 total.

Advlip.jpg 911 × 615; 51 KB
Algorithm for statin-associated myopathy.jpg 810 × 900; 88 KB
Biosynthesis-dielsalder.png 1,523 × 1,602; 77 KB
Biosynthesis-lovd.png 1,442 × 1,177; 60 KB
Cholesterolbiosynthesis.png 1,930 × 2,427; 40 KB
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s2.ogv 20 s, 1,344 × 1,024; 15.49 MB
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s3.ogv 20 s, 1,344 × 1,024; 12.31 MB
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s4.ogv 20 s, 1,344 × 1,024; 10.26 MB
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s5.ogv 19 s, 1,344 × 1,024; 18.75 MB
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s6.ogv 13 s, 1,344 × 1,024; 10.5 MB
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s7.ogv 13 s, 1,344 × 1,024; 9 MB
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s8.ogv 13 s, 1,344 × 1,024; 10.57 MB
Differential-epigenetic-reprogramming-in-response-to-specific-endocrine-therapies-promotes-ncomms10044-s9.ogv 13 s, 1,344 × 1,024; 8.86 MB
Estatina final.png 315 × 209; 13 KB
Estatina.png 578 × 174; 17 KB
Fluvastatina Grupo fluorofenil.jpg 468 × 311; 26 KB
HMG-CoA reductase pathway.svg 500 × 911; 16 KB
Metabolic pathway of a typical statin.png 4,762 × 4,757; 221 KB
Metabolizm i eliminacja statyn oraz potencjalne mechanizmy ich interakcji lekowych 2013.png 3,345 × 1,965; 534 KB
Ogólny mechanizm plejotropowego działania statyn.png 3,507 × 2,480; 403 KB
Schematyczna budowa cząsteczki statyn.png 4,877 × 2,170; 109 KB
Statin final.svg 210 × 139; 14 KB
Statin mechanism v01.svg 652 × 282; 65 KB
Statin pharmacophore 2.png 3,787 × 2,861; 63 KB
Statin pharmacophore.png 665 × 614; 7 KB
Statin pharmacophore.svg 162 × 142; 10 KB
Statin Risks (6941350219).jpg 2,784 × 2,702; 1.08 MB
Statin-Test.png 838 × 759; 66 KB
Statin-use-cardiovascular-disease-death-rate.png 3,400 × 3,844; 1.4 MB
Statin-use-vs-share-of-population-with-high-blood-pressure.png 3,400 × 3,865; 1.37 MB
Statin.svg 385 × 116; 17 KB
Statinfamily.png 1,144 × 315; 48 KB
StatinPathway WP430.png 828 × 743; 62 KB
Statins-1.generation v01.svg 988 × 476; 103 KB
Statins77.png 516 × 461; 38 KB
Vectorial pathway for statin distribution from enterocytes to hepatocytes for their pharmacological action and metabolism and elimination via the bile and kidneys.png 3,654 × 2,375; 697 KB
Wpływ fluwastatyny na wskaźniki lipidowe 01.png 1,747 × 1,900; 69 KB
Wpływ fluwastatyny na wskaźniki lipidowe 02.png 1,747 × 1,891; 46 KB
Wpływ fluwastatyny na wskaźniki lipidowe 03.png 1,751 × 1,900; 78 KB
Wpływ prawastatyny na wskaźniki lipidowe 01.png 1,747 × 1,900; 75 KB
Wpływ prawastatyny na wskaźniki lipidowe 02.png 1,747 × 1,891; 77 KB
Wpływ prawastatyny na wskaźniki lipidowe 03.png 1,755 × 1,900; 82 KB